A Finnish cohort study showed that patients with acromegaly had a 59% higher hazard of cardiovascular morbidity than matched ...
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) subsidiary Marea Therapeutics has dosed the first patient in a Phase 2 ...
Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks, ...
We’ve all heard the expression of someone being ‘larger than life,’ and that usually refers to their personality. This is ...
Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may ...
Blavity on MSN
Why DIY peptides aren’t worth the health risks
The dialogue on health optimization, rapid physical recovery and longevity has been transformed across social media.
Marea Therapeutics, LLC (Marea), a subsidiary of Lisata Therapeutics, Inc. announced the first patient has been dosed in its Phase 2 clinical trial of MAR002 for the treatment of acromegaly.
Dow Jones futures: 51,439 points, down 38. S&P 500 futures: 7,770.50 points, down 6.75. Nasdaq 100 futures: 31,001.75 points, down 60. FTSE 100: 10,516.37 points, up 16.51 since the last update. 8.00 ...
The Framework of 'Human Biology'The subject of this book lies in treating humans as a single biological species. The author, ...
- Vertex Pharmaceuticals VRTX-0.24% (VRTX) fell 0.24% on Oct 5, 2026, despite $0.46B turnover—the highest daily ...
A successful case has been reported of surgical correction of severe dentofacial deformity in a patient with medically controlled acromegaly.
Renaissance paintings reveal Venus models tumor as likely cause of death Art sleuths use endocrine clues in Botticelli and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results